No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
No Data
Unusual Options Activity: ACI, AZN and Others Attract Market Bets, ACI V/OI Ratio Reaches 208.3
AstraZeneca Q2 2024 Earnings Preview
Notable Earnings Before Thursday's Open
AstraZeneca Grows Oncology Portfolio With Pinetree's EGFR Degrader
UBS Sticks to Its Sell Rating for AstraZeneca (AZN)
Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants
No Data